Indeed, chronic inflammation may cause fibrosis and then leads to poor tissue regeneration and affect biocompatibility of nano biomaterials. In brief, a successful implantation is commonly determined by the interaction of cells and molecules between the implanted body and host tissue. The fibrotic encapsulation caused by foreign body response from the different materials was observed via subcutaneous after one month of implantation in order to confirm the biocompatibility and biosafety in vivo (
Figure 6A). Indeed, it was also calculated the intensity of tissue fibrosis effect using Masson’s trichrome staining, which revealed collagen deposition in response to the control treated group (glass) (
Figure 6B). The semi-quantification analysis results are represented in
Figure 6C,D. The value of capsule thickness was the lowest in FN-AgNP 30.2 ppm group (~0.3-fold), comparing to FN-AgNP 15.1 ppm (~0.4-fold), FN-AgNP 75.5 ppm (~0.45-fold) and pure FN (~0.92-fold). And the collagen deposition was also investigated and had a similar trend with capsule thickness [FN-AgNP 30.2 ppm (~0.34-fold), FN-AgNP 15.1 ppm (~0.4-fold), FN-AgNP 75.5 ppm (~0.5-fold) and pure FN (~0.78-fold)]. In addition, the endothelialization marker CD31, and VEGF were also investigated (
Figure 7). As
Figure 7A,B showed, the expression of CD31 was significantly higher in FN-AgNP 30.2 ppm (~1.46-fold) group than in other materials [FN-AgNP 15.1 ppm (~1.26-fold), FN-AgNP 75.5 ppm (~1.12-fold) and pure FN (~1.13-fold)]. And the expression of VEGF was measured at 24 and 48 h through ELISA assay (
Figure 7C). The results showed the expression in FN-AgNP 30.2 ppm group (~1.23-fold to ~1.33-fold) was greater than other materials [FN-AgNP 15.1 ppm (~1.12-fold to ~1.23-fold), FN-AgNP 75.5 ppm (~1.12-fold to ~1.22-fold) and pure FN (~1.08-fold to ~1.11-fold)]. Furthermore, the macrophage polarization was examined and demonstrated as
Figure 8A,B. The marker for M1 polarization, CD86, was significantly lower expressed in FN-AgNP 30.2 ppm group (~0.22-fold), then followed by FN-AgNP 75.5 ppm (~0.38-fold), FN-AgNP 15.1 ppm (~0.44-fold) and pure FN (~0.82-fold) groups (
Figure 8C). Next, CD163 was selected as t M2 polarization marker, then found a reverse trend. Indeed, the tissues in the FN-AgNP 30.2 ppm group (~1.42-fold) was the greatest expression, comparing to FN-AgNP 15.1 ppm (~1.32-fold), FN-AgNP 75.5 ppm (~1.20-fold) and pure FN (~1.12-fold) (
Figure 8D). The above results elucidated FN-AgNP 30.2 ppm could remarkably suppress inflammatory responses and enhance endothelialization ability. The biocompatibility capacity, biological performance, endothelial differentiation ability, and anti-inflammatory response was enhanced by FN-AgNP nanocomposites both in in vivo and the in vivo assay as illustrated in
Figure 9.
Figure 6. Subcutaneous implantation to measure the foreign body reactions induced by various nanomaterials. After four weeks of implantation, (A) H&E staining, white arrows indicate the thickness of the capsule, and (B) Masson’s staining were applied to process further investigations. Scale bar = 100 μm. (C,D) Semi-quantification of capsule thickness and collagen deposition was revealed based on the histology examination. Control group = glass cover slide. * p < 0.05; ** p < 0.01: less than the control (n = 5).
Figure 7. Immunohistochemistry staining for endothelialization marker CD31 affected by the implant materials. (A) The histology images for CD31 were showed after implanting various materials for four weeks. Scale bar = 100 μm. (B) The CD31 expression was also investigated and then semi-quantified according to fluorescence intensity. * p < 0.05; ** p < 0.01: higher than the control (n = 5). Control group = glass cover slide. (C,D) The expression level of VEGF protein was evaluated via ELISA assay at 24 and 48 h, then the fluorescence intensity were semi-quantified by Image J software. Control group = TCPS. Data are the mean ± SD. * p < 0.05; ** p < 0.01: greater than the control (n = 5).
Figure 8. Images of immunohistochemistry staining for macrophage polarization after four weeks subcutaneous implant-ation. (A,B) The IHC staining for markers of macrophage, CD163 (M2, green color) and CD86 (M1, red color), were inves-tigated after implanting various materials. (C) The expression of CD163 was semi-quantified. * p < 0.05; ** p < 0.01: greater than the control (n = 5). (D) The expression of CD86 was also analyzed resulting from fluorescence intensity. * p < 0.05; ** p < 0.01: less than the control. cell nucleus was located by DAPI (blue color). Control group = glass cover slide. Scale bar = 100 μm. Data are presented as mean ± SD (n = 5).
Figure 9. Schematic illustrations that indicate the efficacy of FN-AgNP nanocomposites. FN-AgNP nanocomposite coating enhanced the migration and differentiation ability of MSCs while inhibiting monocyte activation. Furthermore, after im-planted into the rat model, FN-AgNP induced thinner capsule formation, lower collagen deposition, and had an anti-immune response. Based on these evidences, FN-AgNP nanocomposites are suggested to be a promising surface modifi-cation strategy for biomedical applications.
3. Current Insights
Bacterial infection during intravenous injection is a barrier for clinical treatments. The short-term peripheral venous catheters (PVC) are one of the commonly used invasive medical devices in hospitals, but PVC often fail due to vascular or infectious complications such as gram-negative bacteremia or other bloodstream infections before the end of treatments. The above reasons can cause the interruption of treatments that is harmful to patients. Moreover, PVC replacement causes pain on patients and increases treatment costs
[58][10]. A biodegradable water absorption sponge incorporating AgNP had antibacterial properties
[59][11]. Likewise, FN-AgNP nanocomposites can become a novel of surface modification biomaterials for clinical treatments. After coating FN-AgNP on PVC, it may have potential to prevent bloodstream infection and reduce inflammatory response on patients. This kind of surface modified peripheral venous catheters may be developed as a long-term injection medical device to reduce failure rate and decrease treatment costs.
In conclusion, this research suggests that via making composites with fibronectin and AgNP, the behavior of MSCs on the biomaterial such as protein expression of SDF-1α and MMP enzymatic activities can be affected, leading to vascular remodeling. The nanocomposite coating improved blood compatibility, enhanced MSCs migration, proliferation, and EC phenotype as well as attenuated the immune response and ROS generation. With these benefits, the FN-AgNP nanocomposite may be a promising nanobiomaterial to provide a suitable surface coating and delivery technology for implanted cardiovascular devices.